215 related articles for article (PubMed ID: 17593058)
1. The sensitivity and specificity of estrogen receptor, progesterone receptor and HER-2 staining in core biopsies of invasive breast carcinomas.
Frederik P; Cecile C; Tjalma WA
Breast J; 2007; 13(4):436-7. PubMed ID: 17593058
[No Abstract] [Full Text] [Related]
2. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I
J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717
[No Abstract] [Full Text] [Related]
4. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
[TBL] [Abstract][Full Text] [Related]
5. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
Altundag K; Bulut N; Sari E; Harputluoglu H
Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
[No Abstract] [Full Text] [Related]
6. Invasive papillary carcinoma of the breast: an overview of twenty-four cases.
Vural O; Alnak A; Altundag K
Am Surg; 2012 Mar; 78(3):E144-5. PubMed ID: 22524741
[No Abstract] [Full Text] [Related]
7. The prognostic importance of triple negative breast carcinoma.
Mersin H; Yildirim E; Berberoglu U; Gülben K
Breast; 2008 Aug; 17(4):341-6. PubMed ID: 18450442
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancer and brain metastases.
Sait B; Cinar E; Altundag K
Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):84. PubMed ID: 19751969
[No Abstract] [Full Text] [Related]
10. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer.
Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
[No Abstract] [Full Text] [Related]
12. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
13. Synchronous squamous cell carcinoma of the breast and invasive lobular carcinoma.
Sentani K; Tashiro T; Oue N; Yasui W
APMIS; 2007 Dec; 115(12):1422-5. PubMed ID: 18184414
[No Abstract] [Full Text] [Related]
14. Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas.
Helin ML; Helle MJ; Helin HJ; Isola JJ
Arch Pathol Lab Med; 1989 Aug; 113(8):854-7. PubMed ID: 2667495
[TBL] [Abstract][Full Text] [Related]
15. From the guest editor: Triple-negative breast cancer.
Hudis CA
Cancer J; 2010; 16(1):10-1. PubMed ID: 20164684
[No Abstract] [Full Text] [Related]
16. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
17. Are triple-negative and basal-like breast cancer synonymous?
Rakha E; Ellis I; Reis-Filho J
Clin Cancer Res; 2008 Jan; 14(2):618; author reply 618-9. PubMed ID: 18223240
[No Abstract] [Full Text] [Related]
18. [Molecular subtypes and individualized treatment of breast cancer].
Xu BH; Zhang P
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):641-4. PubMed ID: 21122374
[No Abstract] [Full Text] [Related]
19. Receptor status and ethnicity of indigent patients with breast cancer in New York City.
Marti JL; Guth A; Naik A; Hiotis KL
Arch Surg; 2008 Dec; 143(12):1227-30. PubMed ID: 19075177
[TBL] [Abstract][Full Text] [Related]
20. An unusual triple-negative breast carcinoma.
Shousha S; Peston D; Gojis O; Palmieri C
Histopathology; 2009 Sep; 55(3):364-6. PubMed ID: 19723156
[No Abstract] [Full Text] [Related]
[Next] [New Search]